Is the price fair?
What ADPT's price assumes
Adaptive Biotechnologies Corporation did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 7.31× revenue.
7.31
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 9.98
Price / book · as of 2026-Q1
- EV / sales
- 7.47
EV / sales
Details›
- Price / book2026-Q1
- 9.98
- EV / EBIToperating margin −12%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 7.47
- Market capitalisation
- $2.81B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #6 of 29 by Smart Score